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We conducted a multicenter retrospective study to compare the efﬁcacy and toxicity of various chemo-
mobilization regimens: high-dose (HD) cyclophosphamide, HD etoposide (VP-16), and platinum-based che-
motherapies. We reviewed the experiences of 10 institutions with 103 non-Hodgkin lymphoma patients who
had previously only been treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-
based chemotherapy. The mobilization yields for each regimen were analyzed. HD VP-16 mobilized a
signiﬁcantly higher median number of CD34þ cells (16.22  106 cells/kg) than HD cyclophosphamide (4.44 
106 cells/kg) or platinum-based chemotherapies (6.08  106 cells/kg, P < .001). The rate of successful
mobilization (CD34þ cell count 5.0  106 cells/kg) was also signiﬁcantly higher for HD VP-16 (86%) than for
HD cyclophosphamide (45%) or platinum-based chemotherapies (61%, P ¼ .004). The successful mobilization
rate on day 1 of 72% for HD VP-16 was signiﬁcantly higher than the rates for HD cyclophosphamide (13%) and
platinum-based chemotherapies (26%, P < .001). In multivariate analysis, HD VP-16 was a signiﬁcant predictor
of successful mobilization (P ¼ .014; odds ratio, 5.25; 95% conﬁdence interval, 1.40 to 19.63). Neutropenic
fever occurred in 67% of patients treated with HD VP-16. The incidence was similar for HD cyclophosphamide
(58%, P ¼ .454) but was signiﬁcantly lower for platinum-based chemotherapies (12%, P < .001). However, fatal
(grade  4) infection and treatment-related mortality were not observed in this study. In conclusion, the
mobilization yield was signiﬁcantly inﬂuenced by the chemomobilization regimen, and HD VP-16 was a
highly effective mobilization regimen in patients with non-Hodgkin lymphoma.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose (HD) chemotherapy followed by autologous
stem cell transplantation (ASCT) is a curative treatment op-
tion for patients with non-Hodgkin lymphoma (NHL) [1,2].
For successful ASCT, it is essential to collect a sufﬁcient
number of peripheral blood stem cells (PBSCs). Various
chemomobilization regimens have been used in patients
with NHL. HD cyclophosphamide or platinum-based che-
motherapies such as ifosfamide/carboplatin/etoposide (ICE),
cisplatin/cytarabine/dexamethasone (DHAP), and etoposide/dgments on page 78.
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13.10.012methylprednisolone/cytarabine/cisplatin (ESHAP) are com-
monly used in combination with recombinant granulocyte
colony-stimulating factor (G-CSF) [3-7]. Etoposide (VP-16)
has also been considered an effective chemotherapeutic
agent for PBSC mobilization [8]. The efﬁcacy and the toxicity
of HD VP-16 for chemomobilization have been reported in
patients with NHL and multiple myeloma [9-11]. Although
several studies have compared the efﬁcacy of platinum-
based chemotherapies and HD cyclophosphamide in terms
of mobilization yield [4-6], few studies have veriﬁed the
clinical efﬁcacy of HD VP-16 compared with other regimens.
Mobilization failure has signiﬁcant consequences, such as
potential loss of ASCT as a treatment option. Repeated
mobilization attempts increase medical costs and morbidity/
mortality risks. Therefore, it is extremely important to
determine the best chemomobilization regimen [1,12].Transplantation.
S.Y. Hyun et al. / Biol Blood Marrow Transplant 20 (2014) 73e7974However, it is very difﬁcult to evaluate the direct effect of
chemotherapy on mobilization yield in the context of
relapsed NHL, because apheresis is usually performed after
various salvage chemotherapies such as ICE, DHAP, and
ESHAP and prior use of platinum compounds or alkylating
agents is closely related to poor mobilization [13]. Therefore,
we selected patients with NHLwho had previously only been
treated with cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) or rituximab-CHOP (R-CHOP)
chemotherapy and who had not experienced relapse or
progression.We conducted a retrospectivemulticenter study
to determine the impact of various chemomobilization reg-
imens, including HD cyclophosphamide, HD VP-16, and
platinum-based chemotherapies, on PBSC mobilization in
NHL patients only exposed to CHOP-based chemotherapy.
METHODS
Patient Eligibility
One hundred three patients from 10 institutions in Korea were included
by retrospective review of medical records. Patients diagnosed with NHL
who underwent PBSC mobilization for ASCT between January 2005 and
December 2011were included. CHOP or R-CHOP chemotherapy was allowed
as previous chemotherapy and at least a partial response to CHOP-based
chemotherapy was required. We excluded patients who (1) had received
chemotherapeutic drugs other than CHOP or R-CHOP before PBSC mobili-
zation, (2) were aged under 20 or over 65 years, (3) had a history of prior
PBSC mobilization attempts, and/or (4) had a history of malignancies other
than NHL. The protocol was approved by each institution’s institutional
review board.
PBSC Mobilization Protocol
For PBSC mobilization, 5 different chemomobilization regimens were
used. Patient characteristics are summarized in Table 1. Thirty-one patients
received HD cyclophosphamide (4.0 g/m2/day, i.v.) on day 1. Twenty-nine
patients received HD VP-16 (500 mg/m2/day) as 2 doses (i.v.) over 4 hoursTable 1
Patient Characteristics According to Mobilization Regimen
H
Number of patients 3
Median age, yr (range) 4
Male gender 1
Histology (B cell vs. T cell)
B cell subtype 2
Diffuse large B cell lymphoma 2
Thymic large B cell lymphoma
Mantle cell lymphoma
B cell lymphoma, unclassiﬁable
Nodal marginal zone lymphoma
T cell subtype
Anaplastic large cell lymphoma
Peripheral T cell lymphoma, NOS
Angioimmunoblastic T cell lymphoma





BM involvement at diagnosis 1
IPI score 3* 1
Number of previous chemotherapy cycles, median (range)
Previous radiation therapy
Previous use of rituximab 2
Disease status before mobilization
Complete remission 2
Partial remission
Days from last chemotherapy to start of mobilization chemotherapy (range) 3
Median follow-up duration after mobilization start, mo (range) 1
NOS indicates not otherwise speciﬁed; BM, bone marrow; IPI, international progn
* IPI score was missed in 29 patients of 103 patients.on days 1 to 3. Ten patients received an ICE regimen consisting of 5.0 g/m2/
day ifosfamide on day 2, carboplatin on day 2 at a dose calculated using the
Calvert formula (5  [creatinine clearance þ 25]; maximum dose 800 mg),
and 100 mg/m2/day etoposide on days 1 to 3. Twenty-one patients received
a DHAP regimen consisting of 100 mg/m2/day cisplatin on day 1, 4.0 g/m2/
day cytarabine on day 2, and 40 mg/day dexamethasone on days 1 to 4.
Twelve patients received an ESHAP regimen consisting of 40 mg/m2/day
etoposide on days 1 to 4, 500mg/daymethylprednisolone on days 1 to 5, 2.0
g/m2/day cytarabine on day 5, and 25 mg/m2/day cisplatin on days 1 to 4. G-
CSF (10 mg/kg/day) was subcutaneously administered from 1 day after the
completion of mobilization chemotherapy until the last day of apheresis.
Chemotherapy-related toxicities were graded according to the National
Cancer Institute Common Terminology Criteria for Adverse Events, version
4.0 [14].
To determine the ﬁrst day of apheresis, thewhite blood cell (WBC) count
was monitored daily after the completion of chemotherapy and the number
of peripheral blood CD34þ cells or number of peripheral blood hemato-
poietic progenitor cells was also monitored according to each institution’s
policy. PBSC collection was usually initiated when the peripheral blood
CD34þ cell or peripheral blood hematopoietic progenitor cell count was at
least 5  106/L. We also analyzed the mobilization results in patients who
had no information about the peripheral blood CD34þ cell count or he-
matopoietic progenitor cell count on the ﬁrst day of apheresis (68 of 103
patients). If the peripheral blood CD34þ cell or peripheral blood hemato-
poietic progenitor cell count could not be used to determine the ﬁrst day of
apheresis, apheresis was mostly started on the ﬁrst day with aWBC count of
>5.0 109/L. Although the apheresis procedurewas performed according to
each institution’s policy, most apheresis procedures processed a minimum
of 2 times the total blood volumes per day for more than 2 hours. Before
cryopreservation, the collected PBSCs were analyzed for CD34 expression by
ﬂow cytometry. Apheresis was usually continued until sufﬁcient numbers of
CD34þ cells for ASCT had collected.Autologous Stem Cell Transplantation
Ninety-ﬁve patients (92%) underwent frontline ASCT. Six patients did
not receive ASCT because of failed PBSC mobilization (median CD34þ cell
count: 0.12  106 cells/kg), and 2 patients did not receive ASCT because of
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ostic index.
S.Y. Hyun et al. / Biol Blood Marrow Transplant 20 (2014) 73e79 75after ASCT were decided by the protocol of each institution. Most patients
(90%) received intravenous busulfan-based preparation regimens such as
busulfan/cyclophosphamide/etoposide (n ¼ 30), busulfan/cytarabine/
etoposide/melphalan (n ¼ 21), busulfan/thiotepa (n ¼ 20), and busulfan/
melphalan/etoposide (n ¼ 14). Ten percent of patients received another
preparative regimen (eg, mitoxantrone/etoposide/cytarabine/melphalan).
G-CSF (5 mg/kg/day) was used after PBSC infusion and was continued until
the neutrophil count recovered to at least 1.0  109/L on 2 consecutive days.
Platelet transfusionwas performed if the platelet count fell below 2.0  109/
L or if clinically signiﬁcant bleeding occurred.
Statistical Analysis
The efﬁcacy of PBSC mobilization and chemomobilization-related tox-
icities were analyzed according to the chemomobilization regimens. To
simplify the statistical analysis, we classiﬁed the patients into 3 groups:
patients who received HD cyclophosphamide (CTX group), patients who
received HD VP-16 (VP-16 group), and patients who received ICE, DHAP, or
ESHAP (platinum-based chemotherapy group). We deﬁned successful
mobilization as a mobilized CD34þ cell count 5.0  106/kg, adequate
mobilization as a mobilized CD34þ cell count 2.0  106/kg, and failure of
mobilization as a mobilized CD34þ cell count <2.0  106/kg. Neutrophil
engraftment after PBSC infusion was deﬁned as the ﬁrst of 3 consecutive
days with a neutrophil count >.5  109/L and platelet engraftment as the
ﬁrst of 3 days with an unsupported platelet count >20  109/L. Progression-
free survival, overall survival, complete response, and partial response were
deﬁned according to the International Working Group criteria for responses
in NHL [15].
Categorical variables were compared between the groups using the chi-
square test. Multiple comparisons of continuous variables were conducted
using the Kruskal-Wallis test. Continuous variables were also compared
between the 2 groups using the Wilcoxon rank-sum test. Univariate and
multivariate analyses of successful mobilization and successful mobilization
on day 1 were performed using logistic regression models. Survival data
were analyzed using the Kaplan-Meier method, and survival curves were
compared using the log-rank test. P < .05 was deﬁned as statistically sig-
niﬁcant. All statistical calculations were performed with PASW software,
version 20.0 (SPSS, Inc, Chicago, IL).
RESULTS
Patient Characteristics
The clinical characteristics of patients are summarized
according to chemomobilization regimen in Table 1. Age,
gender, international prognostic index score 3, and bone
marrow involvement at the time of diagnosis were compa-
rable among the groups. Patients with advanced disease
(stage IV) were more common in the VP-16 and ICE groups
(P ¼ .008), and complete response status before chemo-
mobilization was more frequently observed in the CTX and
DHAP groups (P ¼ .008). However, the premobilization
clinical characteristics of these patients were similar in terms
of number of previous chemotherapy courses, previous use
of rituximab, previous exposure to radiation therapy, and
time from last chemotherapy to start of chemomobilization.
PBSC Mobilization and Mobilization Yields
The median time from the ﬁrst day of chemotherapy for
mobilization to apheresis was shorter in the CTX and
platinum-based chemotherapy groups than in the VP-16Table 2
Outcomes of Stem Cell Mobilization
HD C
Days from mobilization chemotherapy to apheresis 13
Peripheral blood CD34þ cell count on the ﬁrst day of apheresis, 106/L* 10
Number of days of apheresis 3
Total number of CD34þ cells collected, 106/kg 4.44
CD34þ cells collected on day 1, 106/kg 1.20
CD34þ cells collected on days 1 þ 2, 106/kg 2.66
CD34þ cells collected per apheresis, 106/kg 1.15
* Peripheral CD34þ cell count on the ﬁrst day of apheresis was missed in 68 patgroup (P ¼ .020, Table 2). However, the median number of
days of apheresis was signiﬁcantly lower in the VP-16 group
(1 day) than in other groups (3 days) (P < .001). Based on the
35 available peripheral blood CD34þ cell counts for the ﬁrst
day of apheresis, the VP-16 group also showed a signiﬁcantly
higher count than the other groups (110  106/L versus 9.5 
106/L, P ¼ .010). The VP-16 group had a signiﬁcantly higher
mobilization yield (16.22  106 CD34þ cells/kg) than the
other groups (4.44  106 CD34þ cells/kg for the CTX group,
6.08  106 CD34þ cells/kg for the platinum-based chemo-
therapy group, P < .001). The VP-16 group showed the
highest number of CD34þ cells collected on day 1 (P < .001)
as well as the highest number of CD34þ cells collected on
days 1 and 2 (P < .001). In addition, the number of CD34þ
cells collected per day of apheresis was highest in the VP-16
group (P < .001).
The rate of successful mobilization was highest in the
VP-16 group (86%, P¼ .004, Table 3). Successful mobilization
was observed in 61% of patients who received platinum-
based chemotherapies and in only 45% of patients who
received cyclophosphamide chemotherapy. Successful
mobilization rate on day 1 (72%) and successful mobiliza-
tion rate within the ﬁrst 2 days (76%) were signiﬁcantly
higher in the VP-16 group than in the other groups (P< .001
and P ¼ .002, respectively). Time to successful mobilization
was signiﬁcantly shorter in the VP-16 group (P < .001 [log-
rank test], Figure 1). Although there were no statistical
differences in rate of adequate mobilization, the VP-16
group showed a signiﬁcantly higher rate of adequate
mobilization on day 1 (P ¼ .009). In the VP-16 group, no
patients experienced mobilization failure and mobilization
failure tended to be less frequent compared with the other
groups (P ¼ .051).
Chemomobilization regimen and WBC count on the ﬁrst
day of apheresis 10  109/L were signiﬁcant variables for
successful mobilization in univariate analysis (Table 4).
Multivariate analysis showed that successful mobilization
was independently inﬂuenced by chemomobilization
regimen, especially HD VP-16 (P ¼ .014; odds ratio, 5.25; 95%
conﬁdence interval [CI], 1.40 to 19.63). High WBC count on
the ﬁrst day of apheresis (10  109/L) also showed statis-
tical signiﬁcance (P ¼ .032; odds ratio, 3.85; 95% CI, 1.12 to
13.24). Because peripheral blood CD34þ cell counts on the
ﬁrst day of apheresis were only available for 35 patients, we
decided to exclude this factor from the analyses. In univariate
analysis, the predictive factors for successful mobilization on
day 1 were age <50 years, male gender, chemomobilization
with HD VP-16, and high WBC count on the ﬁrst day of
apheresis (Table 4). In multivariate analysis of successful
mobilization on day 1, chemomobilization with HD VP-16
was the only signiﬁcant variable (P < .001; odds ratio,
17.72; 95% CI, 4.69 to 66.92).TX (n ¼ 31) HD VP-16 (n ¼ 29) Platinum-Based
Chemotherapy (n ¼ 43)
P
(10-18) 15 (13-19) 14 (6-20) .020
(5-15) 110 (1-1415) 9.5 (0-406) .028
(1-9) 1 (1-6) 3 (1-7) .004
(.20-35.50) 16.22 (3.37-151.47) 6.08 (.02-38.94) <.001
(.09-20.90) 15.37 (.17-151.47) 1.57 (.00-23.00) <.001
(.10-33.82) 16.22 (.75-151.47) 4.29 (.02-23.00) <.001
(.07-16.91) 15.37 (.56-151.47) 3.00 (.02-23.00) <.001
ients of 103 patients.
Table 3
Mobilization Efﬁcacy
HD CTX (n ¼ 31) HD VP-16 (n ¼ 29) Platinum-Based Chemotherapy (n ¼ 43) P
Successful mobilization (5  106/kg) 14 (45%) 25 (86%) 26 (61%) .004
Successful mobilization on day 1 4 (13%) 21 (72%) 11 (26%) <.001
Successful mobilization on days 1 þ 2 10 (32%) 22 (76%) 19 (44%) .002
Adequate mobilization (2  106/kg) 25 (81%) 29 (100%) 38 (88%) .051
Adequate mobilization on day 1 12 (39%) 22 (76%) 20 (47%) .009
Mobilization failure (<2  106/kg) 6 (19%) 0 5 (12%) .051
S.Y. Hyun et al. / Biol Blood Marrow Transplant 20 (2014) 73e7976Toxicities of Chemomobilization
Chemomobilization-induced neutrophil nadir developed
a median of 10 days after HDVP-16 or HD cyclophosphamide
chemotherapy and was signiﬁcantly delayed in the
platinum-based chemotherapy group (12 days, P < .001,
Table 5). Absolute neutrophil count at nadir was higher in the
platinum-based chemotherapy group (P < .001). Duration of
absolute neutrophil count <.5  109/L and duration of G-CSF
administration were longer in the VP-16 group than in the
other groups (P< .001 and P< .001, respectively). In addition,
platelet count at nadir was also signiﬁcantly lower in the VP-
16 group (P ¼ .010). Neutropenic fever occurred in 67% of
patients treated with HD VP-16. The incidence of neu-
tropenic fever was similar in the CTX group (58%, P ¼ .454)
but signiﬁcantly lower in the platinum-based chemotherapy
group (12%, P < .001). However, fatal (grade  4) infection
and treatment-related mortality were not observed in this
study (Table 5).Transplantation and Survival
A higher number of collected CD34þ cells were infused for
ASCT in the VP-16 group compared with the other groups (P
< .001, Table 6). The median time to neutrophil engraftment
and platelet engraftment did not differ according to che-
momobilization regimen. At a median follow-up of 26
months after chemomobilization, there were no differences
in progression-free survival or overall survival among the
different chemomobilization regimens used, and there wereFigure 1. Days to collect CD34þ cells 5.0  106 cells/kg. CTX indicates high-
dose cyclophosphamide; VP-16, high-dose etoposide.no reports of therapy-related myelodysplastic syndrome/
acute myeloid leukemia (tMDS/AML) in any group.DISCUSSION
Among various chemotherapy regimens for PBSC mobi-
lization, we demonstrated that HD VP-16 was the most
effective chemomobilization regimen in terms of mobiliza-
tion yield. Moreover, the HD VP-16 regimen achieved suc-
cessful mobilization within a minimum number of days of
apheresis. Although the incidence of neutropenic fever was
higher in the VP-16 group, it might be acceptable because no
patient had a grade 4 infection and there was no treatment-
related mortality.
PBSC mobilization yield is inﬂuenced by various factors,
including age, underlying disease, prior chemotherapies,
disease status, bone marrow involvement at diagnosis, pe-
ripheral CD34þ cell count, and platelet count just before
mobilization [1,13,16-20]. Previous exposure to chemother-
apeutic agents such as platinum compounds or alkylating
agents and a higher number of prior chemotherapy courses
were considered to be especially important predictors of
poor mobilization yield [13,21]. Although several studies
have reported on the efﬁcacy of various chemomobilization
regimens, they have usually included patients with various
underlying diseases and various previous chemotherapeutic
agents, such as platinum compounds and alkylating agents
[22]. Under such conditions, it is very difﬁcult to evaluate the
impact of chemotherapy regimens for PBSC mobilization on
mobilization yield. In the present study, to minimize the
confounding effects of prior chemotherapies, we selected
patients with NHL who had previously only been treated
with CHOP or R-CHOP chemotherapy. This enabled us to
evaluate the direct effects of various chemomobilization
regimens on mobilization yield.
Because PBSC mobilization with G-CSF alone showed
comparable mobilization results in patients who received
less intensive pretreatment [23], we might consider G-CSF
alone in our patients. However, we wanted to evaluate the
impact of various chemomobilization regimens on PBSC
mobilization in NHL patients. Therefore, we did not include
patients who received G-CSF alone for PBSC mobilization in
this study. HD cyclophosphamide and salvage chemother-
apies such as ICE, DHAP, and ESHAP have been commonly
used for PBSC mobilization in patients with NHL. Although
DHAP and ESHAP regimens did not show superior results to
an HD cyclophosphamide regimen [4,5], another study with
an ESHAP regimen reported a higher mobilization yield in
the ESHAP group compared with the HD cyclophosphamide
group [6]. Therefore, the optimal chemomobilization
regimen for NHL has not yet been determined.
VP-16 has been widely used in combination with other
chemotherapeutic drugs for the treatment of malignant
lymphoma and has also been effectively used for chemo-
mobilization [8-11,24-26]. Although HD VP-16 (2.0 g/m2)
Table 4
Univariate and Multivariate Analysis of Successful Mobilization and Successful Mobilization on Day 1
Variables Successful Mobilization Successful Mobilization on Day 1
Univariate Multivariate Univariate Multivariate
P P Odds Ratio (95% CI) P P Odds Ratio (95% CI)
Mobilization regimen (vs. HD cyclophosphamide) .591 .037 <.001 <.001
HD etoposide .002 .014 5.25 (1.40-19.63) <.001 <.001 17.72 (4.69-66.92)
Platinum-based chemotherapy .194 .758 1.18 (.41-3.36) .188 .066 3.38 (.92-12.33)
Age <50 years .224 .043 .323 1.69 (.60-4.76)
Male gender .476 .007 .825 1.12 (.40-3.14)
Ann Arbor stage II or III (vs. IV) .882 .209
Absence of BM involvement at diagnosis .298 .602
No previous radiation therapy .638 .261
Previous use of rituximab .956 .151
Number of chemotherapy cycles (<6 cycles) .535 .691
Interval from last chemotherapy (<1 mo) .372 .298
CR status before mobilization (vs. PR) .797 .314
WBC count on the ﬁrst day of apheresis (10  109/L) .004 .032 3.85 (1.12-13.24) .003 .084 2.65 (.88-8.00)
Platelet count on the ﬁrst day of apheresis (15  109/L) .505 .224
Peripheral blood CD34þ cells on the ﬁrst day of apheresis
(20  106/L)*
Not assessable Not assessable
BM indicates bone marrow; CR, complete remission; PR, partial remission.
* Because of the high rate of missing data, we excluded this factor from univariate and multivariate analyses.
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[27], Mahindra et al. [9] reported signiﬁcantly higher mobi-
lization yields in patients who received HD VP-16 for PBSC
mobilization compared with those who received G-CSF
alone, without an increased risk of tMDS/AML. In addition,
HD VP-16 was shown to be an effective chemomobilization
regimen for patients in whom initial mobilization with HD
cyclophosphamide failed [25]. VP-16, at a dose of either 1.5 or
1.0 g/m2 [26] or an intermediate dose (750 or 600 mg/m2)
[11,24], has also been effective for chemomobilization in
previous studies. Although an intermediate dose of VP-16
(200 mg/m2/day for 3 days) may be superior to HD cyclo-
phosphamide in terms of mobilization yield [24], no studies
have compared the mobilization yields of these various
chemomobilization regimens, including HD VP-16 and
platinum-based chemotherapies. In the present study, we
selected patients who had received HD cyclophosphamide,
HD VP-16, or platinum-based chemotherapies (ICE, DHAP, or
ESHAP) for chemomobilization. Although the patients in the
VP-16 group (1.5 g/m2) more frequently had advanced dis-
ease (stage IV) at the time of diagnosis and less frequently
achieved a complete response before chemomobilization,
the mobilization yield was signiﬁcantly higher in the VP-16
group than in the other groups.
Patients treated with HD VP-16 showed a longer duration
of neutropenia and a longer duration of G-CSF administration
as well as a higher number of platelet transfusions.Table 5
Toxicities According to Mobilization Regimen
HD CTX (n ¼ 31) HD V
Day of neutrophil nadir 10 (5-13) 10 (7
Absolute neutrophil count at nadir (109/L) 6 (0-470) 17 (0
Duration of ANC <.5  109/L, days 5 (1-9) 7 (4
Duration of G-CSF administration, days 8 (2-19) 14 (1
Day of platelet nadir 12 (7-17) 12 (8
Platelet count at nadir (109/L) 37 (18-171) 23 (7
Number of platelet transfusions 2 (0-20) 4 (1
Treatment-related mortality 0 0
Neutropenic fever, number (%) 18 (58%) 14 (6
Grade 4 infection 0 0
tMDS/AML 0 0Moreover, the VP-16 group showed a higher incidence of
neutropenic fever (67%) than the platinum-based chemo-
therapy group. However, we consider HD VP-16 a tolerable
regimen for chemomobilization because no patient experi-
enced severe infection or chemomobilization-related death
and the incidence of neutropenic fever was similar to that in
2 previous studies of HD VP-16 (56% and 61%) [25,26]. In
addition, there were no signiﬁcant differences in median
time to neutrophil engraftment and platelet engraftment
according to chemomobilization regimen. tMDS/AML has
emerged as a serious complication of HD VP-16 but remains
controversial [9,27]. Krishnan et al. [27] reported that pa-
tients who received HD VP-16 (2.0 g/m2) for PBSC mobili-
zation were at a 12.3-fold increased risk of developing
therapy-related AML with 11q23/21q22 abnormalities.
However, a large recent cohort study reported that tMDS/
AML occurred in 2% of patients receiving HDVP-16 (2.0 g/m2)
and in 4% of patients receiving G-CSF alone (P ¼ .62), and the
estimated incidence of tMDS/AML at 5 years was 2% in the
HDVP-16 group and 2.6% in the G-CSF alone group [9]. In the
present study, no patient developed tMDS/AML at a median
follow-up of 26 months after HD VP-16 chemotherapy (1.5 g/
m2). Because studies with an intermediate dose of VP-16 for
chemomobilization also showed a high mobilization yield
and a relatively low incidence of toxicities [11,24], further
clinical trials are needed to determine an appropriate dosage
of VP-16 for chemomobilization.P-16 (n ¼ 29) Platinum-Based Chemotherapy (n ¼ 43) P
-12) 12 (8-17) <.001
-50) 206 (0-2010) <.001
-14) 2 (0-7) <.001
0-19) 7 (3-16) <.001
-14) 13 (9-16) .061
-70) 33 (10-242) .010
-10) 3 (0-20) .036
0
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HD CTX (n ¼ 27) HD VP-16 (n ¼ 28) Platinum-Based Chemotherapy (n ¼ 40) P
Conditioning regimen <.001
Busulfan/thiotepa 0 14 6
Busulfan/cytarabine/etoposide/melphalan 1 12 8
Busulfan/cyclophosphamide/etoposide 16 1 13
Busulfan/melphalan/etoposide 9 0 5
Others 1 1 8
CD34þ cells infused (106/kg) 4.88 (1.45-20.91) 9.15 (4.42-75.73) 5.77 (1.87-22.96) <.001
Days to neutrophil engraftment 10 (6-23) 10 (9-12) 10 (6-29) .105
Days to platelet engraftment 11 (4-42) 10 (7-22) 12 (4-50) .272
2-Year PFS rate after ASCT 72% 81% 69% .263
2-Year OS rate after ASCT 87% 84% 79% .496
PFS indicates progression-free survival; OS, overall survival.
S.Y. Hyun et al. / Biol Blood Marrow Transplant 20 (2014) 73e7978This study has several limitations. Because the peripheral
blood CD34þ cell count on the ﬁrst day of apheresis was only
available for 34% of patients, we could not include peripheral
blood CD34þ cell count when evaluating predictors of suc-
cessful mobilization in this study. However, it did not really
matter because we already had sufﬁcient evidence that pe-
ripheral blood CD34þ cell count on the ﬁrst day of apheresis
is a good predictor of PBSC mobilization yield [16,19,28]. In
addition, the selection of chemomobilization regimen and
the criteria for starting or stopping apheresis were deter-
mined according to each institution’s policy. However, we
consider our results to be reliable for selecting an effective
chemomobilization regimen because the clinical character-
istics that might affect the PBSC mobilization yield were
comparable among the chemomobilization regimens and all
apheresis procedures were usually performed according to
similar guidelines in Korea.
In conclusion, the mobilization yield was signiﬁcantly
inﬂuenced by the chemomobilization regimen, and HD VP-
16 increased PBSC mobilization and reduced the number of
days of apheresis for successful mobilization in patients with
NHL who had previously only been treated with CHOP or
R-CHOP chemotherapy. These results could help guide che-
momobilization regimen selection for patients with NHL
who are being prepared for PBSC mobilization.ACKNOWLEDGMENTS
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